

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (June 21, 2022): June 22, 2022**

**Eledon Pharmaceuticals, Inc.**

(Exact name of Registrant as Specified in Its Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-36620**  
(Commission File Number)

**20-1000967**  
(IRS Employer  
Identification No.)

**19900 MacArthur Blvd.**  
**Suite 550**  
**Irvine, California**  
(Address of Principal Executive Offices)

**92612**  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: 949 238-8090**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

<b>Title of each class</b>	<b>Trading Symbol(s)</b>	<b>Name of each exchange on which registered</b>
Common Stock, \$0.001 par value	ELDN	NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

Eledon Pharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders on June 21, 2022 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted in the following manner with respect to the following proposals:

1. The stockholders of the Company elected each of Keith A. Katkin and John S. McBride as Class II Directors for a three-year term ending at the annual meeting of stockholders to be held in 2025 and until each of their respective successors has been duly elected and qualified. The results of the stockholders' vote with respect to the election of the Class II Directors were as follows:

<b><u>Nominee</u></b>	<b><u>Term Expiring</u></b>	<b><u>For</u></b>	<b><u>Withhold</u></b>	<b><u>Broker Non- Vote</u></b>
Keith A. Katkin	2025	7,330,714	765,231	2,091,204
John S. McBride	2025	7,287,222	808,723	2,091,204

2. The stockholders of the Company ratified the appointment of KMJ Korbin & Company LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. The results of the stockholders' vote with respect to such ratification were as follows:

<b><u>For</u></b>	<b><u>Against</u></b>	<b><u>Abstain</u></b>
10,173,336	10,380	3,433

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: June 22, 2022

By: /s/ David-Alexandre C. Gros  
Name: David-Alexandre C. Gros  
Title: Chief Executive Officer

---

